Dermata Therapeutics (DRMA) Q3 2026 earnings summary

Executive summary

• Tome Foundational Treatment launched DTC on Aug. 25, 2026, generating $74,137 in Q3 sales; late-quarter launch limited initial revenue.

• Early orders included ~30% subscriptions; priorities include expanding brand awareness, sales, distribution and the product portfolio.

• Pivoted from prescription-product R&D toward DTC skincare; substantial doubt about the ability to continue as a going concern remains.

Financial highlights

• Q3 2026 net sales were $74,137, cost of sales $34,008, gross profit $40,129, operating loss $2.858M and net loss $2.821M.

• Q3 operating expenses were $2.898M versus $1.760M in Q3 2025, as SG&A growth more than offset lower R&D; net loss was $1.691M in Q3 2025.

• 9M 2026 net sales were $74,137, operating loss $7.798M and net loss $7.636M, versus net loss of $5.697M in 9M 2025.

• 9M operating cash use was $7.55M; investing cash use was $0.16M and financing cash provided was $5.22M.

Outlook and guidance

• Cash resources are expected to fund operations into Q1 2027; net losses are expected to continue for at least 12 months, and additional capital may be needed.

• Q4 sales and cost of sales are expected to rise with a full quarter of Tome Foundational Treatment sales; lower per-unit shipping costs may improve gross margin as initial inventory sells through.

• Tome Clearing Treatment is in clinical evaluation, with launch targeted for H1 2027, subject to development and commercialization; its first trial participant enrolled Oct. 29, 2026.

• R&D expense is expected to remain relatively low while SG&A increases with marketing, branding, advertising and staffing.